Eupraxia Pharmaceuticals (EPRX) Minority Interest (2022 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 5 years of Minority Interest data on file, last reported at -$1.6 million in Q1 2026.

• On a quarterly basis, Minority Interest fell 1.67% year-over-year to -$1.6 million in Q1 2026; TTM through Mar 2026 was -$1.6 million, a 1.67% decrease from a year earlier, with the FY2025 full-year figure at -$1.6 million, down 1.88% from the prior year.
• Minority Interest for Q1 2026 stood at -$1.6 million, roughly flat from -$1.6 million in the prior quarter.
• Over the last five years, Minority Interest for EPRX reached as high as -$578671.0 in Q4 2022 and fell as low as -$1.6 million in Q1 2026.
• Historically, Minority Interest has averaged -$1.4 million across 5 years, with a median of -$1.6 million in 2024.
• Across the five-year window, Minority Interest sank 128.78% in 2023 and slipped 1.67% in 2026, its largest moves.
• Year by year, Minority Interest stood at -$578671.0 in 2022, then tumbled by 128.78% to -$1.3 million in 2023, then slipped by 18.28% to -$1.6 million in 2024, then fell by 1.88% to -$1.6 million in 2025, then dropped by 0.09% to -$1.6 million in 2026.
• Per Business Quant data, the three most recent Minority Interest figures were -$1.6 million in Q1 2026, -$1.6 million in Q4 2025, and -$1.6 million in Q3 2025.